We demonstrated that a subset of breast cancer cell lines exhibit reduced expression of PTEN mediated by the PRC2 complex, but we wanted to investigate the possible upstream signaling changes that cause increased PRC2 activity at the PTEN promoter. The gene discussed is PTEN; the disease is breast carcinoma.